[go: up one dir, main page]

WO2009028674A1 - ラタノプロスト含有水性医薬組成物 - Google Patents

ラタノプロスト含有水性医薬組成物 Download PDF

Info

Publication number
WO2009028674A1
WO2009028674A1 PCT/JP2008/065564 JP2008065564W WO2009028674A1 WO 2009028674 A1 WO2009028674 A1 WO 2009028674A1 JP 2008065564 W JP2008065564 W JP 2008065564W WO 2009028674 A1 WO2009028674 A1 WO 2009028674A1
Authority
WO
WIPO (PCT)
Prior art keywords
latanoprost
pharmaceutical composition
containing aqueous
aqueous pharmaceutical
filter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/065564
Other languages
English (en)
French (fr)
Inventor
Kohei Yoda
Satoshi Yamazaki
Emi Kawaguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wakamoto Pharmaceutical Co Ltd
Original Assignee
Wakamoto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakamoto Pharmaceutical Co Ltd filed Critical Wakamoto Pharmaceutical Co Ltd
Priority to US12/674,962 priority Critical patent/US9456980B2/en
Priority to JP2009530211A priority patent/JP5327809B2/ja
Priority to ES08828329.6T priority patent/ES2511840T3/es
Priority to KR1020107005330A priority patent/KR101529093B1/ko
Priority to DK08828329.6T priority patent/DK2193795T3/da
Priority to EP08828329.6A priority patent/EP2193795B1/en
Publication of WO2009028674A1 publication Critical patent/WO2009028674A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

　フィルター付き容器に充填された、ラタノプロスト含有水性医薬組成物であって、ラタノプロストのフィルターへの吸着が抑制された水性医薬組成物を提供する。 　フィルター付き容器に封入され、ラタノプロストを含有する水性医薬組成物において、非イオン性界面活性剤を含有すること、及びフィルターの材質が、ポリエーテルスルホン、ポリビニリデンフロライド、ポリカーボネート、及びポリテトラフルオロエチレンからなる群から選ばれる少なくとも１種であることを特徴とする水性医薬組成物。
PCT/JP2008/065564 2007-08-29 2008-08-29 ラタノプロスト含有水性医薬組成物 Ceased WO2009028674A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/674,962 US9456980B2 (en) 2007-08-29 2008-08-29 Latanoprost-containing aqueous pharmaceutical composition
JP2009530211A JP5327809B2 (ja) 2007-08-29 2008-08-29 ラタノプロスト含有水性医薬組成物
ES08828329.6T ES2511840T3 (es) 2007-08-29 2008-08-29 Composición farmacéutica acuosa que contiene latanoprost
KR1020107005330A KR101529093B1 (ko) 2007-08-29 2008-08-29 라타노프로스트 함유 수성 의약 조성물
DK08828329.6T DK2193795T3 (da) 2007-08-29 2008-08-29 Latanoprostholdig vandig farmaceutisk sammensætning
EP08828329.6A EP2193795B1 (en) 2007-08-29 2008-08-29 Latanoprost-containing aqueous pharmaceutical composition

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-222316 2007-08-29
JP2007222316 2007-08-29
JP2008002673 2008-01-10
JP2008-002673 2008-01-10

Publications (1)

Publication Number Publication Date
WO2009028674A1 true WO2009028674A1 (ja) 2009-03-05

Family

ID=40387384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/065564 Ceased WO2009028674A1 (ja) 2007-08-29 2008-08-29 ラタノプロスト含有水性医薬組成物

Country Status (8)

Country Link
US (1) US9456980B2 (ja)
EP (1) EP2193795B1 (ja)
JP (1) JP5327809B2 (ja)
KR (1) KR101529093B1 (ja)
DK (1) DK2193795T3 (ja)
ES (1) ES2511840T3 (ja)
PT (1) PT2193795E (ja)
WO (1) WO2009028674A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119305A1 (en) * 2009-04-14 2010-10-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of quaternary ammonium compounds in dissolving of latanoprost
WO2012141334A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
JP2013213052A (ja) * 2012-02-27 2013-10-17 Rohto Pharmaceutical Co Ltd 眼科用組成物キット
JP2019535713A (ja) * 2016-11-09 2019-12-12 テジュン ファーマシューティカル カンパニー リミテッドＴａｅｊｏｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 眼圧降下用点眼組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
PL2887923T3 (pl) 2012-08-24 2023-08-14 Sun Pharmaceutical Industries Limited Preparat okulistyczny polioksylipidu lub polioksylowego kwasu tłuszczowego i leczenie chorób oczu
BR112016027379A2 (pt) * 2014-05-23 2018-06-26 Ocular Tech Sarl formulações tópicas e seus usos
JP2018532809A (ja) 2015-11-10 2018-11-08 サン ファーマ グローバル エフジーイー 局所製剤およびその使用
DK3423076T3 (da) 2016-02-29 2024-07-08 Sun Pharmaceutical Ind Ltd Topisk cyclosporinholdige formuleringer og anvendelser deraf
CA3104060A1 (en) * 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520368A (ja) * 1998-07-14 2002-07-09 アルコン ラボラトリーズ， インコーポレイテッド プロスタグランジン製品
JP2005160972A (ja) * 2003-11-10 2005-06-23 Rohto Pharmaceut Co Ltd 眼科用液剤入り容器及び眼科用液剤
JP2006503913A (ja) * 2002-10-24 2006-02-02 スキャンポ・アーゲー・（ユーエスエイ）・インク 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物
JP2007511295A (ja) * 2003-11-14 2007-05-10 メディカル・インスティル・テクノロジーズ・インコーポレイテッド 注入装置及び注入方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2729859B2 (ja) 1993-04-16 1998-03-18 わかもと製薬株式会社 可逆性熱ゲル化水性医薬組成物
CA2153234C (en) 1993-04-16 1999-02-16 Masanobu Takeuchi Aqueous drug composition having property of reversible thermosetting gelation
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
JP3876355B2 (ja) 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
JP2003095924A (ja) 2001-07-16 2003-04-03 Wakamoto Pharmaceut Co Ltd 熱ゲル化人工涙液
EP1495747B1 (en) 2002-04-04 2013-01-16 Nipro Corporation Liquid drug container
JP4357159B2 (ja) 2002-07-22 2009-11-04 ニプロ株式会社 薬液容器
JP4744775B2 (ja) 2002-11-20 2011-08-10 ニプロ株式会社 薬液容器
CA2498233C (en) * 2002-09-09 2012-08-14 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
JP2004123729A (ja) * 2002-09-09 2004-04-22 Santen Pharmaceut Co Ltd ラタノプロストを有効成分とする澄明な点眼液
US7947295B2 (en) 2003-06-13 2011-05-24 Alcon, Inc. Ophthalmic compositions containing a synergistic combination of two polymers
KR20110134525A (ko) 2003-06-13 2011-12-14 알콘, 인코퍼레이티드 시너지성의 2개의 폴리머 배합물을 포함하는 안과용 조성물
CN1845856A (zh) * 2003-09-02 2006-10-11 大塚制药株式会社 排出构件、具有该排出构件的排出容器和点眼容器
JP4947977B2 (ja) 2003-10-31 2012-06-06 わかもと製薬株式会社 可逆性熱ゲル化水性組成物
US20050287325A1 (en) * 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520368A (ja) * 1998-07-14 2002-07-09 アルコン ラボラトリーズ， インコーポレイテッド プロスタグランジン製品
JP2006503913A (ja) * 2002-10-24 2006-02-02 スキャンポ・アーゲー・（ユーエスエイ）・インク 高眼圧症および緑内障の処置のための方法およびラタノプロスト含有組成物
JP2005160972A (ja) * 2003-11-10 2005-06-23 Rohto Pharmaceut Co Ltd 眼科用液剤入り容器及び眼科用液剤
JP2007511295A (ja) * 2003-11-14 2007-05-10 メディカル・インスティル・テクノロジーズ・インコーポレイテッド 注入装置及び注入方法

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010119305A1 (en) * 2009-04-14 2010-10-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of quaternary ammonium compounds in dissolving of latanoprost
WO2012141334A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
CN103596572A (zh) * 2011-04-12 2014-02-19 株式会社·R-技术上野 水性眼用组合物
JP2013213052A (ja) * 2012-02-27 2013-10-17 Rohto Pharmaceutical Co Ltd 眼科用組成物キット
JP2019535713A (ja) * 2016-11-09 2019-12-12 テジュン ファーマシューティカル カンパニー リミテッドＴａｅｊｏｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 眼圧降下用点眼組成物
JP7058650B2 (ja) 2016-11-09 2022-04-22 テジュン ファーマシューティカル カンパニー リミテッド 眼圧降下用点眼組成物

Also Published As

Publication number Publication date
KR101529093B1 (ko) 2015-06-16
JP5327809B2 (ja) 2013-10-30
EP2193795A1 (en) 2010-06-09
KR20100056499A (ko) 2010-05-27
ES2511840T3 (es) 2014-10-23
US9456980B2 (en) 2016-10-04
JPWO2009028674A1 (ja) 2010-12-02
EP2193795B1 (en) 2014-10-01
PT2193795E (pt) 2014-10-22
DK2193795T3 (da) 2014-11-03
US20110065790A1 (en) 2011-03-17
EP2193795A4 (en) 2013-09-18

Similar Documents

Publication Publication Date Title
WO2009028674A1 (ja) ラタノプロスト含有水性医薬組成物
USD661607S1 (en) Liquid chromatograph
USD635261S1 (en) Stent
USD635262S1 (en) Stent
USD648403S1 (en) Rockable platform
USD640561S1 (en) Bottle
USD678638S1 (en) Paint application container
USD638735S1 (en) Bead
WO2008024640A3 (en) Biodegradable elastomeric scaffolds containing microintegrated cells
WO2009029847A8 (en) Compositions and methods of using proislet peptides and analogs thereof
WO2011064782A3 (en) Multi-component stent-graft system for implantation in a blood vessel with multiple branches
WO2005102396A3 (en) Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
USD657499S1 (en) Earplug
USD652079S1 (en) Ballpoint pen
WO2009120182A3 (en) Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or actives
PL2443482T3 (pl) Urządzenia biomedyczne, materiały polimerowe i soczewki kontaktowe je zawierające
WO2008031045A3 (en) Aquaretic and natriuretic polypeptides lacking vasodilatory activity
WO2011014365A3 (en) Providing link to portion of media object in real time in social networking update
WO2007143204A3 (en) Compositions and methods for modifying cell surface glycans
WO2006105062A3 (en) Altered antibody fc regions and uses thereof
PL1913138T3 (pl) Sposoby wytwarzania pankreatyny w proszku o niskiej zawartości wirusa
WO2007100826A3 (en) Living hinge
WO2008024250A3 (en) Reusable envelopes
WO2009082458A3 (en) Contact angle attenuations on multiple surfaces
WO2009041052A1 (ja) 合成樹脂製スラスト滑り軸受

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08828329

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12674962

Country of ref document: US

Ref document number: 2008828329

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009530211

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107005330

Country of ref document: KR

Kind code of ref document: A